Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages

      This paper is only available as a PDF. To read, Please Download here.


      purpose: To determine the efficacy, dose-response relationship, and safety of 30, 60, and 90 mg of a single intravenous dose of an aminobisphosphonate, pamidronate (APD), for the treatment of moderate to severe hypercalcemia of malignancy.
      patients and methods: Patients with histologically proven cancer and a corrected serum calcium level of at least 12.0 mg/dL after 48 hours of normal saline hydration were enrolled in a double-blind, multicenter, randomized clinical trial. Pamidronate in 30-, 60-, or 90-mg doses was administered as a single 24-hour infusion. Serum calcium corrected for albumin, urine hydroxyproline, and calcium excretion, and serum parathyroid hormone (PTH) (1–84) were determined before and after pamidronate therapy.
      results: Thirty-two men and 18 women entered the study. A dose-response relationship for normalization of corrected serum calcium was seen after pamidronate administration. Corrected serum calcium normalized in 40% of patients who received 30 mg, in 61% of patients who received 60 mg, and in 100% of patients who received 90 mg of pamidronate. The decline in the serum calcium level was associated with decreased osteoclastic skeletal resorption evidenced by a decrease in urine calcium and hydroxyproline excretion. Among those with a normalized corrected serum calcium level, the mean (median) duration of normalization of the corrected serum calcium value was 9.2 (4), 13.3 (5), and 10.8 (6) days in the 30-, 60-, and 90-mg treatment groups, respectively. The response of hypercalcemia to pamidronate was not significantly influenced by the presence of skeletal metastases. PTH 1–84, suppressed in patients on entry into this study, increased to a greater extent in those patients with osteolytic skeletal metastases compared with those with humoral hypercalcemia of malignancy. Clinical improvement, including improved mental status and decreased anorexia, accompanied the decline in the corrected serum calcium level in all three treatment groups. Side effects included low-grade fever, asymptomatic hypocalcemia, hypomagnesemia, and hypophosphatemia.
      conclusions: A single-dose infusion of 60 to 90 mg of pamidronate was highly effective and well tolerated and normalized corrected serum calcium in nearly all patients (61% to 100%) with hypercalcemia of malignancy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fisken RA
        • Heath DA
        • Bold AM
        Hypercalcemia-a hospital survey.
        Q J Med. 1980; 196: 405-418
        • Bertolini DR
        • Nedwin GE
        • Bringman TS
        • et al.
        Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors.
        Nature. 1986; 319: 516-518
        • Mundy GR
        Hypercalcemic factors other than parathyroid-related protein.
        Endocrinol Metab Clin North Am. 1989; 18: 779-794
        • Suva LJ
        • Winslow GA
        • Wettenhall EG
        • et al.
        A parathyroid hormone-related protein implicated in a malignant hypercalcemia: cloning and expression.
        Science. 1987; 237: 893-896
        • Mangin M
        • Webb AC
        • Dreyer BE
        • et al.
        Identification of the complementary DNA encoding a parathyroid hormone-like peptide from a human tumor associated with hypercalcemia of malignancy.
        in: 29th ed. Proc Natl Acad Sci U S A. 85. 1988: 597-601
        • Strewler GJ
        • Stern PH
        • Jacobs JW
        • et al.
        Parathyroid hormone-like protein from human renal carcinoma cells: structural and functional homology with parathyroid hormone.
        J Clin Invest. 1987; 80: 1803-1807
        • Horiuchi N
        • Caulfield MP
        • Fisher JE
        • et al.
        Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro.
        Science. 1988; 238: 1566-1568
        • Joppner H
        • Abou-Samra AB
        • Uneno S
        • et al.
        The PTH-like peptide associated with humoral hypercalcemia of malignancy and parathyroid hormone bind to the same receptor on the plasma membranes of ROS 17/2.8 cells.
        J Biol Chem. 1988; 263: 8557-8560
        • Mundy GR
        • Wilkinson R
        • Heath PA
        Comparative study of available medical therapy for hypercalcemia of malignancy.
        Am J Med. 1983; 74: 421-432
        • Jacobs TP
        • Siris ES
        • Bilezekian JP
        • et al.
        Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
        Ann Intern Med. 1981; 94: 3212-3216
        • Sleeboom HP
        • Bijvoet OL
        • van Oosterom AT
        • et al.
        Comparison of intravenous (3 amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumor-induced hypercalcemia.
        Lancet. 1983; 2: 239-243
        • Ryzen E
        • Martodam RR
        • Troxell M
        • et al.
        Intravenous etidronate in the management of malignant hypercalcemia.
        Arch Intern Med. 1985; 145: 449-452
        • Body JJ
        • Borkowski A
        • Cleeren A
        • Bijvoet OLM
        Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxy propylidene diphosphonate.
        J Clin Oncol. 1986; 4: 1177-1183
        • Fleish H
        Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism.
        Recent Results Cancer Res. 1989; 116: 1-28
        • Nussbaum SR
        • Zahradnik RJ
        • Lavigne JR
        • et al.
        A highly sensitive two-site immunoradiometric assay of parathyroid hormone and its clinical utility in evaluating patients with hypercalcemia.
        Clin Chem. 1987; 33: 1364-1367
      1. 29th ed. Manual of oncologic therapeutics. JB Lippincott, Philadelphia1990
        • Perlia CP
        • Gubish NJ
        • Walter J
        Mithramycin treatment of hypercalcemia.
        Cancer. 1970; 25: 389-394
        • Suki WN
        • Yium JJ
        • Minden MV
        • et al.
        Acute treatment of hypercalcemia with furosemide.
        N Engl J Med. 1970; 283: 836-840
        • Warrell Jr, RP
        • Israel R
        • Frisane M
        • et al.
        Gallium nitrate for acute treatment of cancer-related hypercalcemia.
        in: A randomized, double-blind comparison to calcitonin. 29th ed. Ann Intern Med. 108. 1988: 669-674
        • Thalassinos NC
        • Joplin GF
        Failure of corticosteroid therapy to correct the hypercalcemia of malignant disease.
        Lancet. 1970; 2: 537-538
        • Reitsma PH
        • Teitelbaum SL
        • Bijvoet OLM
        • Kahn AJ
        Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD) and disodium dichloromethylidene biphosphonate (Cl MDP) on rat macrophage-mediated bone resorption in vitro.
        J Clin Invest. 1982; 70: 927-933
        • Thiebaud D
        • Jaeger P
        • Jacquet AF
        • Burckhardt P
        A single-day treatment of tumor induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
        J Bone Miner Res. 1986; 1: 555-562
        • Singer FR
        • Ritch PS
        • Lad TE
        • et al.
        Treatment of hypercalcemia of malignancy with intravenous etidronate.
        in: A controlled, multicenter trial. 29th ed. Arch Intern Med. 151. 1991: 471-476
        • Gurney H
        • Kefford R
        • Stuart-Harris R
        Renal phosphate threshold and response to pamidronate in humoral hypercalcemia of malignancy.
        Lancet. 1989; 2: 241-244
        • Burckhardt P
        • Thiebaud D
        • Pery L
        • Von Fliedner V
        Treatment of tumorinduced osteolysis by APD.
        Recent Results Cancer Res. 1989; 116: 54-66
        • Brasier AR
        • Nussbaum SR
        The hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery.
        Am J Med. 1988; 84: 654-660
        • Brasier AR
        • Wang CA
        • Nussbaum SR
        Recovery of parathyroid hormone secretion after parathyroidectomy.
        J Clin Endocrinol Metab. 1988; 66: 495-500
        • Coggeshall J
        • Merrill W
        • Hande K
        • Des Prez R
        Implications of hypercalcemia with respect to diagnosis and treatment of lung cancer.
        Am J Med. 1986; 80: 325-328
        • Ralston SH
        • Gallacher SJ
        • Patel U
        • et al.
        Cancer-associated hypercalcemia: morbidity and mortality.
        Ann Intern Med. 1990; 112: 499-504
        • Green L
        • Donehower RC
        Hepatic toxicity of low doses of mithramycin in hypercalcemia.
        Cancer Treat Rep. 1984; 68: 1379-1381
        • Ralston SH
        • Dryburgh FJ
        • Cowan RA
        • et al.
        Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer-associated hypercalcemia.
        Lancet. 1985; 2: 907-910
        • Sawyer N
        • Newstead C
        • Drummond A
        • Cunningham J
        Effect of infusion rate on response to single shot pamidronate (APD) in the treatment of hypercalcemia of malignancy [abstract].
        J Bone Miner Res. 1989; 4: 775
        • Cantrill JA
        • Buckler HM
        • Anderson DC
        Low dose intravenous 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
        Ann Rheum Dis. 1986; 45: 1012-1018
        • vanholten-Verzantvoort AT
        • Bijvoet OLM
        • Cleton FJ
        • et al.
        Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
        Lancet. 1987; 2: 983-985
        • Shinoda H
        • Adamek G
        • Felix R
        • et al.
        Structure-activity relationship of various bisphosphonates.
        Calcif Tissue Int. 1983; 35: 87-93